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work/productivity was measured by the validated Work Productivity and Activity
Impairment (WPAI) instrument. MRUwasmeasured by traditional health care pro-
vider, emergency room (ER) visits and hospitalization in the past 6 months. Com-
parisons were made between respondents who reported as diagnosed with AS
(excluding other auto-immune diseases) vs. respondents without AS (non-AS
group).RESULTS:Of 19,954 survey respondents, 52 (0.26%)were diagnosedwithAS.
The average age was 43.0 (SD 13.5) years with 57.7% of males. AS group reported
higher Charlson comorbidity index score than in non-AS group (1.4 vs. 0.2). The
most common comorbidities (25% of patients) were headache, insomnia, gingi-
vitis, body pain, sleep difficulties, arrhythmia, anxiety and arthritis. AS group had
lower mean scores of PCS (42.9 vs. 49.6) and MCS (44.1 vs. 46.2), more patients
visited health care providers (71.2% vs. 49.7%), ER (30.8% vs. 17.6%) and hospitalized
(19.2% vs. 5.7%) in the past 6 months vs. non-AS group. Also, AS group reported
more work productivity loss (absenteeism/presenteeism) with 40.1% vs. 23.3% and
impairment in daily activity with 36.7% vs. 20.3% in non-AS group. All comparisons
between AS and non-AS groups were statistically significant at P 0.05, except
MCS. CONCLUSIONS: From the China NHWS results, AS patients suffer from im-
pairment in quality of life, work/productivity loss, more co-morbidities and use of
medical services. The findings indicate there is still an unmet medical need in AS
patients in China.
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OBJECTIVES: To compare patient-reported outcomes (PROs) achieved with sus-
tained, reduced, or suspended etanercept (ETN) in combination withmethotrexate
(MTX) over 52 weeks after induction of sustained response with combination ETN/
MTX therapy in a sub-analysis of the developing countries from the multinational
PRESERVE trial.METHODS:Data from9developing countries of Asia, Latin America
and Europe were included in this sub-analysis. Patients with moderately active RA
(DAS28 of 3.2 and 5.1) who achieved DAS28 low disease activity (LDA; DAS28
3.2; average Weeks12–36 and at Week 36) during the 36-week open-label induc-
tion phase with ETN 50mg QW plus MTX (E50/M) were randomized to double-blind
treatment with E50/M, ETN 25mg QW plus MTX (E25/M), or placebo plus MTX (P/M)
for an additional 52 weeks. PROs included Health Assessment Questionnaire
(HAQ), EuroQol-5D (EQ-5D), Functional Assessment of Chronic Illness Therapy
(FACIT), Medical Outcomes Study sleep problem index II (MOS), and Brief Pain
Inventory (BPI). RESULTS:Of 491 patients enrolled, 388 were randomized blindly at
Week 36: E50/M (n127), E25/M (n134), or P/M (n127). Significant improvement
from baseline (P0.0001) in all PROswas observedwith E50/M atWeek 36. Adjusted
mean changes in HAQ, EQ-5D, BPI and MOS from Weeks 36–88 were statistically
significantly smaller with E50/M and E25/M versus P/M (P0.05), indicating less
deterioration. Adjusted mean change in FACIT was significantly smaller for E50/M
but not E25/M versus P/M (P0.05). A higher percentage of patients in the E50/M
(57.5%) and E25/M (56.0%) groups had a HAQ 0.5 compared to those in the P/M
group (43.3%) at Week 88 (P0.05). CONCLUSIONS: In patients with moderate RA,
after induction and maintenance of LDA, ETN full- and reduced-dose regimens
were superior to step-down treatment with MTX alone in their effects on func-
tional and quality of life endpoints. Minimal differences in PROs were observed
between the full- and reduced-dose treatment groups.
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OBJECTIVES: The objective of the present investigation was investigation of com-
parative clinical outcome profile and cost effectiveness of DMARDs, NSAIDs, ste-
roid steroids, herbal drugs.METHODS: It was prospective, longitudinal, open label,
parallel group study consisting of four groups with 40 patients in each cohort. The
patients were grouped according to the treatment received (DMARDs, NSAIDs,
steroid steroids, IL-1 inhibitors). The data regarding health outcomeand costswas
assessed before and after the threemonth regimenusingHAQDI, DAS -28, VAS and
EQ5D3L and case report form. RESULTS: The mean change in scores of patients
subjected to HAQ DI was 0.54 in DMARD; 0.46 in NSAID; 0.50 in steroid drug treated
and 0.63 in IL-1 inhibitor treated cohorts. The mean change in scores of patients
subjected to DAS-28 was 0.54 in DMARD; 0.52 in NSAID; 0.79 in steroid drug treated
and 1.39 in IL-1 inhibitor treated cohorts. The mean change in scores of patients
subjected to VAS was 15 in DMARD; 11 in NSAID; 2.4 in steroid drug treated and 39
in IL-1 inhibitor treated cohorts. Themean change in scores of patients subjected
to EQ5D3L was 0.26 in DMARD; 0.41 in NSAID; 0.39 in steroid drug treated and 0.72
in IL-1 inhibitor treated cohorts. The mean values varied significantly among all
the groups (p0.01). The average cost effectiveness was 331.48 for DMARD; 206.52
for NSAID; 224.32 for steroid drug treated and 188.41 for IL-1 inhibitor treated
cohorts. The QALDs in each treatment groupwhichwas 18 in DMARD; 15 in NSAID;
12 in steroid drug treated and 25.5 in IL-1 inhibitor treated cohorts. The incremen-
tal cost effectiveness ratio was determined between IL-1 and DMARD and was
found to be equal to 0.15. CONCLUSIONS: IL-1 inhibitor therapy is the most cost
effective for rheumatoid arthritis in western Indian population.
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OBJECTIVES: Examine improvement in physical function, HRQOL & work produc-
tivity in a subset of Asian patients from the golimumab (GLM) RA & AS trials.
METHODS: RA patients with inadequate response to MTX in GO-FORWARD
(N444) & AS patients despite NSAID/DMARDs in GO-RAISE (N356) were random-
ized to SC GLM (50or100mg) or placebo q4wks. At wk16, RA patients with 20%
improvement in tender & swollen joint count or AS patients with 20% improve-
ment in both total back pain &morning stiffness entered early escape (i.e.,placebo
received GLM 50mg & GLM 50 mg received GLM 100mg).Physical function was
assessed using HAQ (0-3) in RA & BASFI (0-10) in AS. HRQOL was assessed using
SF-36 PCS (0-100) & SF-36 MCS (0-100). Impact of disease on work productivity was
assessed using a productivity VAS (0-10). Clinically meaningful improvement was
defined as improvement of 0.25 point in HAQ, 2 points in BASFI or 5 points in
SF-36 PCS &MCS. RESULTS:At baseline, RA patients (N48) had amean HAQ score
of 1.35, & AS patients (N83) had a mean BASFI score of 3.25; PCS & MCS were 31.5
& 42.5, respectively, in RA, & 33.2 & 41.3 in AS; productivity VASwas 5.6 in RA & AS.
Compared to placeboMTX-treated RA patients (N22), GLMMTX-treated pa-
tients (N26) had greater mean improvement in HAQ (0.54 vs -0.01, p0.01), PCS
(7.9 vs -0.40, p0.01) & work productivity (-2.4 vs -0.4, p0.05), the change in MCS
wasnot statistically significant (3.0 vs 2.1, p0.05). Compared to placebo-treatedAS
patients (N17), GLM-treated patients (N66) had greater mean improvements in
BASFI (1.51 vs 0.28, p0.05), MCS (5.3 vs -1.1, p0.05) & work productivity (-2.9 vs
-0.9, p0.05); change in PCS was not statistically significant (9.0 vs 5.7,p0.05).
Greater proportions of RA patients in GLM group than placebo achieved clinically
meaningful improvement in HAQ (73.1% vs 30%, p0.01), PCS (61.5% vs 25%,
p0.01) & MCS (50% vs 35%,p0.31); in AS, similar trends in clinically meaningful
improvement in BASFI, PCS & MCS observed between groups. Improvements in
HAQ, BASFI, SF-36 & work productivity in GLM-treated patients were sustained
over wk52 and 104, & were consistent across populations (Asia vs non-Asia).
CONCLUSIONS: Patients from Asia with RA or AS treated with GLM demonstrated
improved physical function & HRQOL.
PMS21
FUNCTIONAL IMPAIRMENT, DISEASE ACTIVITY, AND DURATION OF DISEASE
INDEPENDENTLY AFFECT THE QUALITY OF LIFE IN PATIENTS WITH
RHEUMATOID ARTHRITIS
Chiu YM1, Wang JD2, Lai MS3
1Changhua Christian Hospital, Changhua City, Changhua County, Taiwan, 2National Cheng
Kung University College of Medicine, Tainan, Taiwan, 3National Taiwan University, Taipei,
Taiwan
OBJECTIVES: Rheumatoid arthritis (RA) has an extensive impact on quality of life
(QOL) in RA patients. The aim of this study was to determine the effects of func-
tional impairment, disease activity andduration of disease onQOL after controlling
other risk factors. METHODS: This was a cross-sectional study comprised of 230
consecutive patients with RA from a rheumatology clinic. Quality of life was mea-
sured using Taiwan version of short form of World Health Organization Quality of
Life (WHOQOL-BREF) questionnaire. Disease activity was assessed by the Disease
Activity Score 28 (DAS28), functional disability by theHealthAssessmentQuestion-
naire (HAQ). Data on demographics, duration of disease, and income level were
also collected. The QOL of the RA patients was compared with 229 age-, sex-,
marriage-, and education-matched healthy control patients taken from a national
survey in Taiwan. Multiple regression analyses were conducted to study predictors
for impairment of QOL. RESULTS: RA patients have significantly lower score in
physical and psychological domain compared with healthy population, but they
showed a higher score in the environment domain ofWHOQOL-BREF. After adjust-
ment of HAQ, age, and other factors, we foundDAS28 score and duration of disease
significantly affect the QOL on almost all four domains. CONCLUSIONS: Functional
impairment, disease activity and duration independently affect the QOL of RA
patients. Future outcome research must take account of all these factors.
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OBJECTIVES: Rheumatoid Arthritis (RA) is a seriously debilitating disease affecting
37 in every 1000 adult populations in China.We assessed symptoms, functionality,
and quality of life in RA patients who are treated with Infliximab in China.
METHODS: Amulti-center study was conducted from June 2009 to October 2011 in
RA patients at 37 urban hospitals in 21 cities in China. Symptoms were measured
by morning stiffness, and pain Visual Analogue Scale (VAS) scores defined from 0
(no pain) to 100 (severe pain). The Health Assessment Questionnaire (HAQ) was
used to measure functional status (scores 0-3). Quality of life was measured by the
mental (MCS) and physical component summary (PCS) scores of the Short Form-12
(SF-12). Comparisons were made between patients who were treated Infliximab at
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